Stock Track | Akeso Plummets 9.65% Intraday After Partner's Clinical Trial Disappointment

Stock Track

May 04

Akeso's stock plummeted 9.65% during intraday trading on Monday, following negative news regarding a key clinical trial for a co-developed drug.

The decline came after Akeso's overseas partner, Summit Therapeutics, announced that the interim progression-free survival analysis of their jointly developed ivonescimab (a PD-1/VEGF bispecific antibody) in a global Phase 3 trial for first-line non-small cell lung cancer did not reach statistical significance. While the study will continue, the market interpreted the lack of an immediate positive signal as a setback for the drug's prospects.

Analysts noted that the failure to achieve significance at the interim analysis raised concerns about the drug's competitive positioning in the crowded oncology market. Akeso experienced a catch-up decline as trading resumed after the holiday period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1104766980"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104766980\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104766980?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104766980","market":"hk","top_or_hot":-1,"title":"Stock Track | Akeso Plummets 9.65% Intraday After Partner's Clinical Trial Disappointment","media":"Stock Track","content":"<p>Akeso's stock plummeted 9.65% during intraday trading on Monday, following negative news regarding a key clinical trial for a co-developed drug.</p><p>The decline came after Akeso's overseas partner, Summit Therapeutics, announced that the interim progression-free survival analysis of their jointly developed ivonescimab (a PD-1/VEGF bispecific antibody) in a global Phase 3 trial for first-line non-small cell lung cancer did not reach statistical significance. While the study will continue, the market interpreted the lack of an immediate positive signal as a setback for the drug's prospects.</p><p>Analysts noted that the failure to achieve significance at the interim analysis raised concerns about the drug's competitive positioning in the crowded oncology market. Akeso experienced a catch-up decline as trading resumed after the holiday period.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Akeso Plummets 9.65% Intraday After Partner's Clinical Trial Disappointment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Akeso Plummets 9.65% Intraday After Partner's Clinical Trial Disappointment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-04 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Akeso's stock plummeted 9.65% during intraday trading on Monday, following negative news regarding a key clinical trial for a co-developed drug.</p><p>The decline came after Akeso's overseas partner, Summit Therapeutics, announced that the interim progression-free survival analysis of their jointly developed ivonescimab (a PD-1/VEGF bispecific antibody) in a global Phase 3 trial for first-line non-small cell lung cancer did not reach statistical significance. While the study will continue, the market interpreted the lack of an immediate positive signal as a setback for the drug's prospects.</p><p>Analysts noted that the failure to achieve significance at the interim analysis raised concerns about the drug's competitive positioning in the crowded oncology market. Akeso experienced a catch-up decline as trading resumed after the holiday period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1104766980","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104766980","pubTimestamp":1777858720,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Akeso's stock plummeted 9.65% during intraday trading on Monday, following negative news regarding a key clinical trial for a co-developed drug.The decline came after Akeso's overseas partner, Summit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"股票追踪|合作伙伴临床试验令人失望康方生物盘中暴跌9.65%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"Akeso's stock plummeted 9.65% during intraday trading on Monday, following negative news regarding a key clinical trial for a co-developed drug.The decline came after Akeso's overseas partner, Summit Therapeutics, announced that the interim progression-free survival analysis of their jointly developed ivonescimab (a PD-1/VEGF bispecific antibody) in a global Phase 3 trial for first-line non-small cell lung cancer did not reach statistical significance. While the study will continue, the market interpreted the lack of an immediate positive signal as a setback for the drug's prospects.Analysts noted that the failure to achieve significance at the interim analysis raised concerns about the drug's competitive positioning in the crowded oncology market. Akeso experienced a catch-up decline as trading resumed after the holiday period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}